GSA Capital Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

GSA Capital Partners’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-399,039	Closed	-$475K	–	2035
2022 Q3	$475K	Buy	+399,039	New	+$622K	0.06%	607
2021 Q1	–	Sell	-20,706	Closed	-$99K	–	1615
2020 Q4	$99K	Buy	+20,706	New	+$105K	0.02%	1100
2020 Q2	–	Sell	-15,576	Closed	-$99K	–	1256
2020 Q1	$99K	Sell	15,576 -3,906	-20%	-$31.3K	0.02%	900
2019 Q4	$203K	Sell	19,482 -7,696	-28%	-$56K	0.02%	1251
2019 Q3	$107K	Buy	+27,178	New	+$220K	0.01%	1271
2015 Q3	–	Sell	-14,000	Closed	-$1.23M	–	2094
2015 Q2	$1.23M	Buy	14,000 +7,691	+122%	+$658K	0.05%	724
2015 Q1	$468K	Buy	+6,309	New	+$446K	0.02%	1429
2014 Q1	–	Sell	-5,637	Closed	-$340K	–	1863
2013 Q4	$340K	Buy	5,637 +637	+13%	+$34.6K	0.03%	1114
2013 Q3	$304K	Buy	+5,000	New	+$355K	0.02%	1142

Other funds holding CLVS

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

GSA Capital Partners's CLVS Position: Q4 2022 in Review

GSA Capital Partners sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 399,039 shares — an estimated $475K sold.

GSA Capital Partners first reported a position in CLVS in Q3 2013 and held it in 9 quarters. The position peaked at $1.23M in Q2 2015. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

GSA Capital Partners reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
GSA Capital Partners sold 399,039 Clovis Oncology, Inc. shares in Q4 2022, an estimated $475K.
GSA Capital Partners first reported a position in Clovis Oncology, Inc. in Q3 2013 and held it in 9 quarters.
GSA Capital Partners's Clovis Oncology, Inc. position peaked at $1.23M in Q2 2015.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.